(November 21, 2017) Neurodyn Cognition Inc. recently presented the latest data from a Multiple Ascending Dose (MAD) study and pharmaco-EEG analysis of Memogain® at the 10th Annual Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, Massachusetts on November 1 to 4.
Memogain® is a patented pro-drug of an existing Alzheimer’s drug, galantamine (Reminyl®, Razadyne®), with 10-15x greater brain bioavailability. The drug has a unique and safe mechanism of sensitization of neuronal nicotinic acetylcholine receptors, most notably the alpha-7 subtype, with strong pre-clinical evidence of disease modification. Memogain has successfully completed an enhanced phase I clinical trial, which demonstrated excellent safety and tolerability even at elevated doses, and additionally indicated improved working memory in both young and elderly healthy subjects. The enhanced tolerability is likely to improve patients’ compliance at all stages of treatment – current estimates of drop–out rates range from 30-50% due to lack of perceived benefit and GI side effects.
Neurodyn Cognition Inc. is also confirmed to present at the British Pharmacological Society’s ‘Pharmacology 2017’ , taking place in London, UK from December 11 to 13, and has a pending abstract submission for the American Society for Clinical Pharmacology and Therapeutics (ASCPT) taking place March 15 t0 18 in Washington, DC.
“This is the first time the British Pharmacological Society’s flagship meeting accepted late-breaking abstract submissions and we are thrilled to be among those accepted and recognized for high-impact science,” says Kenneth Cawkell, Director and CEO of Neurodyn Cognition Inc.
The poster can be viewed here:
About Neurodyn Cognition Inc.
Neurodyn Cognition Inc. (www.neurodyncognition.ca) is a spin-out company of Neurodyn Life Sciences Inc. (www.neurodyn.ca) set up for the purposes of taking Memogain rapidly to the marketplace. The company maintains offices in Canada and Germany, and is currently conducting clinical trials in Europe.